• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Elevation of serum creatine kinase induced by anti-thyroid drugs: Two case reports and a literature review
Int J Clin Pharmacol Ther. 2022 Sep 2. doi: 10.5414/CP204269. Online ahead of print.ABSTRACTAnti-thyroid drugs (ATDs), such as methimazole (MMI) and propylthiouracil (PTU), are the most common treatment options for hyperthyroidism. Although effective, well-known adverse effects include agranulocytosis, toxic hepatitis, vasculitis, and arthralgias. Myalgia and elevation of serum creatine kinase (CK) are relatively rare, with an unclear mechanism. Rapid decrease in the thyroid hormone level may be associated with ATD-related myopathy; however, direct effects of the drug on muscle tissue cannot be excluded. Here we report on ...
Source: International Journal of Clinical Pharmacology and Therapeutics - September 2, 2022 Category: Drugs & Pharmacology Authors: Yuqi Si Fenli Su Haoxiang Wu Chuangpeng Shen Source Type: research

064 Imilimumab/nivolumab induced paraspinal myositis causing dysphagia
We present a case of Imilimumab/Nivolumab-induced posterior paraspinal muscles myositis. A 78 year-old man with metastatic melanoma with hepatic, osseous, and lymph node spread had 3 weeks of dysphagia to solids but not liquids, 2 months after his last cycle of immunotherapy. He complained of hoarse voice, weight loss, unsteadiness and falls. Examination revealed symmetrical, normal palatal rise without tongue wasting or fasciculation. Speech was hypernasal with poor pharyngeal phonation. There was no fatigue nor ptosis nor extra-ocular motor weakness. Small muscle hand wasting was modest in keeping with general cachexia. ...
Source: Journal of Neurology, Neurosurgery and Psychiatry - May 27, 2022 Category: Neurosurgery Authors: Warner, G. Tags: Poster Presentations Source Type: research

A Successful Case of Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab with Multisystem Immune-related Adverse Events
Intern Med. 2022 Apr 30. doi: 10.2169/internalmedicine.9393-22. Online ahead of print.ABSTRACTA 63-year-old man with hepatitis C was treated with atezolizumab plus bevacizumab for unresectable diffuse hepatocellular carcinoma (HCC). After four cycles of atezolizumab plus bevacizumab, the diffuse HCC markedly shrank; however, he complained of general fatigue, loss of appetite, and slight loss of muscle strength in the lower legs. He was diagnosed with isolated adrenocorticotropic hormone deficiency (IAD), hypothyroidism, and myopathy, suggesting multisystem immune-related adverse events (irAEs). After administration of hydr...
Source: Internal Medicine - May 1, 2022 Category: Internal Medicine Authors: Hidemi Hayashi Koji Sawada Takumu Hasebe Shunsuke Nakajima Jun Sawada Yuri Takiyama Yumi Takiyama Toshikatsu Okumura Mikihiro Fujiya Source Type: research

Pages: 1  2  3  4  5  6